Dynamic Contrast Enhanced MRI (DCE-MRI) Assessment of the Vascular Changes Induced With Bevacizumab Alone and in Combination With Interferon-alpha in Patients With Advanced Renal Cell Carcinoma: a phase II, open labelled, randomised, multicentre trial.
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Bevacizumab (Primary) ; Interferon alpha-2a
- Indications Renal cancer
- Focus Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 28 Feb 2010 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
- 24 Apr 2009 Roche added as trial sponsor, East and North Hertfordshire NHS Trust as lead trial centre as reported by ISRCTN.